Non-invasive biomarkers offer potential alternatives to invasive kidney biopsy for monitoring renal allograft pathologyNew non-invasive tests may replace invasive kidney transplant biopsies

Frontiers in Medicine Published July 3, 2026 Study authors: Luke Barr, Fareeha Mubin, John Friedewald, Sook Hyeon Park DOI ↗ Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Note that non-invasive biomarkers like donor-derived cell-free DNA are being developed to replace invasive biopsies.

This mini review synthesizes current knowledge regarding non-invasive biomarkers for the management of kidney transplants. The scope includes several candidates such as donor-derived cell-free DNA, gene expression profiling, urinary chemokines, extracellular vesicles, microRNA, and Torque Teno Virus. These markers are currently being developed or are already in clinical use to monitor allograft pathology.

The primary argument is that these non-invasive methods provide a potential alternative to the standard of care, which involves invasive kidney biopsies. The review highlights that while biopsy remains a standard for diagnosis, its invasive nature presents significant limitations for routine surveillance and prognostication of renal allografts.

A limitation noted by the authors is that the review discusses candidate biomarkers but does not provide specific clinical trial data or comparative efficacy statistics. Clinical application is currently limited by the need for more robust evidence regarding these markers' performance relative to biopsy.

Clinicians may consider these biomarkers as emerging tools in the management of renal allografts. However, they are not yet established as standard replacements for biopsy due to a lack of large-scale trial data.

When a patient receives a kidney transplant, doctors must constantly monitor the health of the new organ. Currently, one way to check for problems is through a biopsy. This involves taking a physical tissue sample from the kidney, which is an invasive procedure.

Researchers are looking at non-invasive biomarkers as a better alternative. These include things like donor-derived cell-free DNA, gene expression profiling, and certain proteins found in urine or blood. Some of these markers are already being used in clinics, while others are still being developed to help predict how well a transplant will perform over time.

While these tests offer a less invasive way to track organ health, it is important to note that this review looks at potential candidates rather than specific trial results. The goal is to find reliable ways to monitor the graft without the risks of a biopsy.

What this means for you:

Non-invasive markers like cell-free DNA and urine tests may offer safer ways to monitor kidney transplant health.

Common questions

What are the non-invasive tests being studied?

Several types of markers are being explored to monitor kidney transplants. These include donor-derived cell-free DNA, gene expression profiling, urinary chemokines, extracellular vesicles, microRNA, and Torque Teno Virus. Some of these are already in clinical use while others are still being developed as candidates.

Why are doctors looking for alternatives to a biopsy?

The current standard method, a kidney biopsy, is invasive. This means it involves a procedure that can be physically taxing. Researchers are developing non-invasive biomarkers to overcome these limitations and provide a safer way to monitor the health of a transplanted organ.

Study Details

Study typeSystematic review

EvidenceLevel 1

PublishedJun 2026

View Original Abstract ↓

Significant advancements have been made in kidney transplantation, with a wealth of immunosuppressive and antimicrobial therapies that have significantly improved graft survival. Despite these accomplishments, the ability to promptly identify kidney allograft pathology for these therapies has been limited by the reliance on kidney biopsy as the gold-standard diagnostic modality, which is invasive. To overcome these limitations, non-invasive biomarkers have been developed over the past two decades. Donor-derived cell-free DNA, gene expression profiling, urinary chemokines, extracellular vesicles, microRNA, and Torque Teno Virus are candidates near or already in clinical use. This mini-review discusses the strengths and limitations of these biomarkers for the surveillance and prognostication of renal allografts.

Non-invasive biomarkers offer potential alternatives to invasive kidney biopsy for monitoring renal allograft pathologyNew non-invasive tests may replace invasive kidney transplant biopsies

Common questions

Study Details

Intrawound tobramycin plus vancomycin did not reduce deep infection risk compared with vancomycin alone in high-risk tibial fractures

Adding Antibiotics to Bone Surgery Didn't Lower Infection Risk

Clinical research that matters. Delivered to your inbox.

Non-invasive biomarkers offer potential alternatives to invasive kidney biopsy for monitoring renal allograft pathologyNew non-invasive tests may replace invasive kidney transplant biopsies

Common questions

Study Details

Intrawound tobramycin plus vancomycin did not reduce deep infection risk compared with vancomycin alone in high-risk tibial fractures

Adding Antibiotics to Bone Surgery Didn't Lower Infection Risk

Clinical research that matters. Delivered to your inbox.

Related in Infectious Disease

From Other Specialties